199 results about "Imidazolidine" patented technology

Disclosed are biocidal compositions comprising mixtures of formaldehyde-releasing imidazolidines, such as 1,3-dimethylol-5,3-dimethylhydantoin, and 3-isothiazolones stabilized with low levels of copper salts.

The present invention provides the synthesis process of (3aS, 6aR)-1, 3-dibenzyl-tetrahydro-4H-furo[3, 4-d]-imidazolyl-2, 4(1H)-dione. Compound 1, 3-dibenzyl imidazolidine-2-one-2H-furo[3, 4-d]-imidazolyl-2, 4, 6-trione is made to produce enantiotropic selective ring-opening reaction with fatty alcohol and arylkyl alcohol under the catalysis of chiral amine to produce (4S, 5R)-1, 3-dibenzyl-5-alkoxycarbonyl-2-oxyimidazolidine-4-carboxylic acid, which is then reduced with borohydride and ring-closed under Lewis acid catalysis inside organic solvent to produce (3aS, 6aR)-1, 3-dibenzyl-tetrahydro-4H-furo[3, 4-d]-imidazolyl-2, 4(1H)-dione in the total yield over 88 %. The said process uses easy-to-obtain material, has mild reaction condition and is suitable for industrial production.

The synthesis process of 1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolyl-2-imine relates to farm pesticide imidacloprid synthesizing process. In dimethylforamide as solvent and with quaternary ammonium salt as catalyst, potassium carbonate, 2-chloro-5-chloro methyl pyridine and excessive imidazolyl alkane are condensed to produce 1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolyl -2-imine. The present invention has short reaction period, high product purity and high product yield.

Novel crystal modifications of (5S)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonylmethyl]-5-methyl-imidazolidine-2,4-dione are disclosed together with processes for preparing such modifications, pharmaceutical compositions comprising such a modification, and the use of such a modification in therapy.

According to the present invention, a compound represented by formula (I):

wherein Q is:

A is a hydrogen atom, a halogen atom, —ORa or a C_1-4 alkyl group which may be substituted by one or more halogen atoms; E is independently selected from a C_1-6 alkyl group; m is selected from integers from 0 to 3; R² and R³ are independently selected from a C_1-6 alkyl group; X¹ and X² are independently selected from O and S; Y is selected from an arylene group and a divalent 5- or 6-membered monocyclic or 8- to 10-membered condensed heterocyclic group, wherein the arylene group and the heterocyclic group may be substituted by 1 to 3 substituents independently selected from E¹; E¹ is independently selected from a hydroxyl group, a halogen atom, a C_1-4 alkyl group, a cyano group, a C_1-4 alkoky group, a carbamoyl group, a C_1-4 alkylcarbamoyl group, a di(C_1-4 alkyl)carbamoyl group, an amino group, a C_1-4 alkylamino group, a di(C_1-4 alkylamino group, a sulfamoyl group, a C_1-4 alkylsulfamoyl group and a di(C_1-4 alkyl)sulfamoyl group; Z is —CON(—Ra)—, —CO—, —COO—, —NRa—C(═NH)NRb—, —NRa—C(═N—CN)NRb—, —N(—Ra)COO—, —C(═NH)—, —SO₂—, —SO₂N(—Ra)—, —SO₂NR¹—, —N(—Ra)CO—, —N(—Ra)CON(—Rb)—, —N(COR¹)CO—, —N(—Ra)SO₂—, —N(SO₂R¹)SO₂—, —N(—Ra)— or —N(—Ra)SO₂N(—Rb)—; R¹ is independently a hydrogen atom, a hydroxyl group, a C_1-6 alkyl group which may be substituted by one or more substituents, a heterocyclic group which may be substituted by one or more substituents, an aryl group which may be substituted by one or more substituents, a C_3-8 cycloalkyl group which may be substituted by one or more substituents or a C_3-8 cycloalkenyl group which may be substituted by one or more substituents, or a salt, prodrug or solvate thereof is provided. Furthermore, a pharmaceutical composition containing the compound, and the like are also provided.

The invention provides a method of treating condensation waste water in imidacloprid production and recovering imidazole, filtering and aerating the condensation waste water and purifying by ultrahigh cross-linking absorption resin; neutralizing effluent water from primary absorption stage and then passing through macroporous poly-TRIM absorption resin, and distilling, cooling and filtering effluent water from secondary absorption stage and recovering course salts, where the distilled water is recycled in the original process, or aerobically treated to reach the effluent standard and discharged; the macroporous poly-TRIM absorption resin is regenerated by HCl desorption, processed by methanol every multiple batches and able to be repeatedly used; and the eluting liquid is neutralized and frozen so as to separate out imidazole; and the moter liquids are merged many times to recover imidazole; the ultrahigh cross-linking absorption resin is desorbed with methanol and washed with water and then able to be recycled.

The present application relates to novel imidazolidine-2,4-dione derivatives of the general formula (I), where R¹, R², R³, R⁴, X, and Y are variables. Said materials have an antiproliferative activity. They are particularly useful for treating pathological conditions and diseases, such as cancer, that are linked to abnormal cell proliferation. The invention also relates to pharmaceutical compositions containing said materials and to the use thereof for preparing a drug.

This invention provides a process for conducting Suzuki coupling reactions. The processes of the present invention make use of N-heterocyclic carbenes as ancillary ligands in Suzuki couplings of aryl halides and aryl pseudohalides. A Suzuki coupling can be carried out by mixing, in a liquid medium, at least one strong base; at least one aryl halide or aryl pseudohalide in which all substituents are other than boronic acid groups, wherein the aryl halide has, directly bonded to the aromatic ring(s), at least one halogen atom selected from the group consisting of a chlorine atom, a bromine atom, and an iodine atom; at least one arylboronic acid in which all substituents are other than chlorine atoms, bromine atoms, iodine atoms, or pseudohalide groups; at least one metal compound comprising at least one metal atom selected from nickel, palladium, and platinum, wherein the formal oxidation state of the metal is zero or two; and at least one N-heterocyclic carbene. One preferred type of N-heterocyclic carbene is an imidazoline-2-ylidene of the formulawherein R1 and R2 are each, independently, alkyl or aryl groups having at least 3 carbon atoms, R3 and R4 are each, independently, a hydrogen atom, a halogen atom, or a hydrocarbyl group.

The invention provides a synthesis process of 2-chlorin-5-((2-(nitryl methylene) imidazoline-1-yl) methyl) pyridine. Particularly, the method comprises the following steps: preparing 2-nitryl methylene imidazolidine from vinylidene chloride serving as a raw material; and reacting the 2-nitryl methylene imidazolidine with a 2-chlorin-5-chloromethyl pyridine compound so as to form 2-chlorin-5-((2-(nitryl methylene) imidazoline-1-yl) methyl) pyridine. The synthesis process has the advantages that raw materials are easily available, production cost is low, conditions are mild, and the operation is simple and convenient; moreover, synthesis process is environmentally-friendly and suitable for industrial production.

The invention belongs to the field of cosmetics, and particularly relates to a collagen gel capable of moisturizing, revitalizing and nourishing. The collagen gel comprises glycerinum, butanediol, dipropylene glycol, propylene glycol, trehalose, glycine betaine, colostrums, hydrolyzed collagen, phospholipid, xanthan gum, pyridoxine, PCA ((pyrrolidone hydroxy acid)) sodium, sodium lactate, Beta-glucose, polysorbate 20, polysorbate 80, imidazolidinyl urea, iodopropynyl butylcarbamate, EDTA (Ethylene Diamine Tetraacetic Acid) disodium, essence and purified water. The gel is mild and has no simulation, is remarkable in moistening effect, can nourish the skin deeply, is applicable to moistening of a collagen mask, bottoming for massaging and acoustic wave beauty therapy when in a professional care, and also can be used as nutrient lotions for efficiently moistening when in home health care. The collagen gel is applicable to dry and dry skin and mature skin.

The present invention discloses an RPAK/imidazolidine/RGD ternary conjugate, a preparation method and uses thereof. According to the present invention, L-Lys is adopted as a linking arm to link 1,3-dioxy-2-[(4-oxyacetic acid)phenyl]-4,4,5,5-tetramethylimidazoline, an RPAK tetrapeptide having a thrombolysis effect, and a RGD tetrapeptide having an anti-thrombosis effect to obtain the RPAK/imidazolidine/RGD ternary conjugate represented by a formula I, wherein the RPAK/imidazolidine/RGD ternary conjugate integrally has effects of BBB crossing, thrombolysis and NO removing. The RPAK/imidazolidine/RGD ternary conjugate has high NO free radical clearance activity, excellent thrombolysis activity and excellent anti-thrombosis activity. In vivo anti-stroke activity test results show that: with the RPAK/imidazolidine/RGD ternary conjugate, nerve functions of stroke rats can be effectively protected, brain infarct volume of the stroke rats can be reduced, anti-stroke activity is provided, and the RPAK/imidazolidine/RGD ternary conjugate can be adopted as a clinical drug for brain infarction treatment.

The invention provides a special cleaning solution for slightly alkaline chemical equipment. The special cleaning solution comprises components in parts by weight as follows: 15-17 parts of disodium hexadecyldiphenyl ether disulfonate, 6-8 parts of rosin-based imidazolidine polyether, 7-9 parts of sorbitan ester polyoxyethylene ether, 2-3 parts of sodium carbonate, 0.8 parts of sodium citrate, 3-5 parts of sodium sulfite, 1.5-2.5 parts of 1,2-diethoxysilyl ethane, 0.8-1.2 parts of a chelating agent, 1.5-2.5 parts of a thickener, 0.5 parts of a builder, 0.1 parts of plant essential oil, 18 parts of ethanol and 15-20 parts of deionized water. The special cleaning solution for the slightly alkaline chemical equipment is very good, environment-friendly and harmless to human bodies while the excellent decontamination capacity is guaranteed.

The present invention relates to novel imidazolidine derivatives of the formula I,

• • in which B, E, W, Y, R, R², R³, R³⁰, e and h have the meanings given herein. The compounds of the formula I are valuable pharmaceutically active compounds which are suitable, for example, for treating inflammatory diseases, for example, rheumatoid arthritis, or allergic diseases. The compounds of the formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4, which belongs to the integrin group. They are generally suitable for treating diseases which are caused by, or associated with, an undesirable degree of leukocyte adhesion and/or leukocyte migration or in which cell-cell or cell-matrix interactions, which are based on the interactions of VLA-4 receptors with their ligands, play a role. The invention furthermore relates to processes for preparing the compounds of the formula I, to their use and to pharmaceutical preparations which comprise compounds of the formula I.

A process for producing methionine advantageously in view of cost, while efficiently recovering useful components, is provided, including the following steps: (1) hydrolyzing 5-[2-(methylthio)ethyl]imidazolidine-2,4-dione in the presence of a basic potassium compound; (2) introducing carbon dioxide into the reaction solution obtained in step (1) to thereby precipitate methionine, and separating the resulting slurry into a precipitate and a mother liquor; (3) concentrating the mother liquor obtained in step (2), mixing the resulting concentrate with a lower alcohol, introducing carbon dioxide into the resulting mixture to thereby precipitate methionine and potassium hydrogencarbonate, and separating the resulting slurry into a precipitate and a mother liquor; and (4) concentrating the mother liquor obtained in step (3), treating the resulting concentrate by heating at a temperature of from 150 to 200° C., and recycling the treated solution for use in step (3).

The new benzoyl urea derivatives of formula (I) wherein the meaning of X and Y independently are hydrogen atom, hydroxy, benzyloxy, amino, nitro, C₁-C₄ alkylsulfonamido optionally substituted with a halogen atom or halogen atoms, C₁-C₄ alkanoylamido optionally substituted with a halogen atom or halogen atoms, C₁-C₄ alkoxy, aroyl-carbamoyl optionally substituted with halogen atom or C₁-C₄ alkyl or C₁-C₄ alkoxycarbonyl group, or the neighboring X and Y groups optionally form together with one or more identical or different additional hetero atom and —CH═ and/or —CH₂— groups an optionally substituted 4-7 membered homo- or heterocyclic ring, preferably morpholine, pyrrole, pyrrolidine, oxo- or thioxo-pyrrolidine, pyrazole, pyrazolidine, imidazole, imidazolidine, oxo- or thioxo-imidazole or imidazolidine, 1,4-oxazine, oxazole, oxazolidine, triazole, oxo- or thioxo-oxazolidine, or 3-oxo-1,4-oxazine ring, V and Z independently are hydrogen or halogen atom, cyano, C₁-C₄ alkyl, C₁-C₄ alkoxy, trifluoromethyl, hydroxy or optionally esterized carboxyl group, W is oxygen atom, as well as C₁-C₄ alkylene, C₂-C₄ alkenylene, aminocarbonyl, —NH—, —N(alkyl)-, —CH₂O—, —CH₂S—, —CH(OH)—, —OCH₂— group, wherein the meaning of alkyl is a C₁-C₄ alkyl group—, when the dotted bonds () represent simple C—C bonds then U is hydroxy group or hydrogen atom or when W is C₁-C₄ alkylene or C₂-C₄ alkenylene group, then one of the dotted bonds () can represent a further double C—C bond and in this case U means an electron pair, which participate in the double bond and optical antipodes, racemates and the salts thereof are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor. Furthermore objects of the present invention are the pharmaceutical compositions containing new benzoyl urea derivatives of formula (I) or optical antipodes or racemates or the salts thereof as active ingredients and processes for producing these compounds and pharmaceutical compositions.

The invention discloses a metal cleaner, which is composed of the following ingredients in parts by weight: 4-5 parts of deionized water, 2-3 parts of octanol, 2-3 parts of tetramethyl ammonium bromide, 4-5 parts of fatty alcohol-polyoxyethylene ether sulfate, 1-2 parts of glycerin monostearate, 8-9 parts of sodium phosphate, 1-2 parts of imidazolidine, 1-2 parts of mineral oil, 1-2 parts of sodium silicate, 6-7 parts of polyvinyl alcohol, 2-3 parts of tributyl phosphate, 2-3 parts of lignosulfonate, 4-5 parts of fatty alcohol-polyoxyethylene ether, 1-2 parts of benzotriazole, 1-2 parts of dodecyl trimethyl ammonium sulfate and 1-2 parts of oleoyl amino acid. The metal cleaner disclosed by the invention has the advantages of low alkaline, few bubbles and environment friendliness, has a very strong deoiling effect under lower temperature and is low in corrosivity.

The invention discloses a corrosion inhibitor for inhibiting H2S/CO2 corrosion and a preparation method thereof. The corrosion inhibitor is a composition, and its composition and content are: (A) imidazolidinethione derivative 20% by weight to 60% by weight %; (B) acetylene alcohol 5% by weight to 20% by weight; (C) surfactant 1% by weight to 10% by weight; (D) solvent 20% by weight to 50% by weight, wherein the preparation of imidazolidinethione derivatives The raw materials are thiourea, β-hydroxyethylethylenediamine and fatty acids. The corrosion inhibitor is especially suitable for inhibiting H2S/CO2 corrosion in oil fields.